An obituary on DAV-132—authors’ viewpoint on the current limits of pivotal trials in clinical microbiome research-Reference-Cited by-同舟云学术

An obituary on DAV-132—authors’ viewpoint on the current limits of pivotal trials in clinical microbiome research

Author:

Vehreschild Maria J G T¹,Biehl Lena M²,Dane Aaron³,de Kraker Marlieke E A⁴^ORCID,Timbermont Leen⁵,van Werkhoven C Henri⁶

Affiliation:

1. Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt , Frankfurt am Main , Germany

2. Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne , Cologne , Germany

3. Danestat Consulting Limited , Macclesfield , UK

4. Infection Control Program, Geneva University Hospitals and Faculty of Medicine , Geneva , Switzerland

5. Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp , Antwerp , Belgium

6. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University , Utrecht , the Netherlands

Funder

European Federation of Pharmaceutical Industries and Associations

EFPIA

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

Reference12 articles.

1. Superbugs and superdrugs—SMi’s 12th annual conference—overcoming resistance. 17–18 March 2010, London, UK;Oni;IDrugs,2010

4. The potential impact of gut microbiota on your health: current status and future challenges;Sirisinha;Asian Pac J Allergy Immunol,2016